Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788112 · ClinicalTrials.gov registry record · Phase 1
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00788112: Completed Phase 1 study, sponsored by University of California, San Francisco.
NCT00788112 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788112, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- DRUG vorinostat
- OTHER immunohistochemistry staining method
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-08-11 |
| Phase | Phase 1 |
What the finished NCT00788112 record still lists
NCT00788112 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00788112 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00788112 about?
NCT00788112 is a clinical study titled "Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast". RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well vorinostat works in treating women with ductal carcinoma in situ of the breast.
What is the current status of trial NCT00788112?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-07. Estimated completion is 2015-08-11.
What interventions are being tested in trial NCT00788112?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), vorinostat (DRUG), immunohistochemistry staining method (OTHER), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00788112?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00788112's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia